| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cauloside F targets multiple pathways involved in inflammation, oxidative stress, and tumor growth. It has anti-inflammatory, antioxidant, hepatoprotective, and anticancer effects. The compound modulates immune responses and protects against oxidative damage. It inhibits tumor cell proliferation. Cauloside F is a triterpenoid saponin from Clematis akebioides. Further studies are needed to fully characterize its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro, Cauloside F is a triterpenoid saponin isolated from Clematis akebioides. It exhibits anti-inflammatory, antioxidant, hepatoprotective, and anticancer effects. The compound modulates immune responses and protects against oxidative damage. It inhibits tumor cell proliferation. Its bioactivity has been characterized in various cell-based assays. Further in vitro studies are ongoing to fully characterize its pharmacological effects.
|
| ln Vivo |
In vivo, Cauloside F has been studied for its anti-inflammatory, antioxidant, hepatoprotective, and anticancer effects. It modulates immune responses and protects against oxidative damage. The compound inhibits tumor cell proliferation. It has potential therapeutic and environmental applications. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
In vitro enzyme assays for Cauloside F involve measuring its antioxidant, anti-inflammatory, and anticancer activities. Antioxidant activity is assessed using DPPH or other free radical scavenging assays. Anti-inflammatory activity is measured by assessing inhibition of pro-inflammatory cytokine production. Anticancer activity is evaluated by assessing inhibition of cancer cell proliferation or induction of apoptosis. Hepatoprotective activity is assessed in hepatocyte models of injury. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Cauloside F are conducted in cancer cell lines, immune cells, and hepatocytes. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Inflammatory markers are measured by ELISA. Antioxidant activity is assessed by measuring intracellular ROS levels. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Cauloside F in vivo studies are conducted in animal models of inflammation, cancer, and liver injury. Animals are treated with Cauloside F via oral administration or injection. For anti-inflammatory studies, animal models of inflammation are used. For anti-tumor studies, tumor-bearing mice are used. For hepatoprotection studies, animal models of liver injury are used. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Cauloside F (MW 1237.38-1237.4 g/mol, C59H96O27) is a triterpenoid saponin. It is isolated from Clematis akebioides and Caulopyhllum robustum. The compound is soluble in organic solvents. It is stable under recommended storage conditions. Cauloside F has anti-inflammatory, antioxidant, hepatoprotective, and anticancer effects. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies.
|
| Toxicity/Toxicokinetics |
Cauloside F is generally well-tolerated in preclinical studies. The compound is a natural triterpenoid saponin with established safety profiles. Its anti-inflammatory, antioxidant, hepatoprotective, and anticancer effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
According to reports, stem glycoside F has been found in both Pulsatilla chinensis and ivy, and relevant data are available for reference.
Cauloside F is a triterpenoid saponin from Clematis akebioides and Caulopyhllum robustum with anti-inflammatory, antioxidant, hepatoprotective, and anticancer effects. It modulates immune responses, protects against oxidative damage, and inhibits tumor cell proliferation. Its molecular formula is C59H96O27 with a molecular weight of 1237.38-1237.4 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C59H96O27
|
|---|---|
| Molecular Weight |
1237.37736225128
|
| Exact Mass |
1236.613
|
| CAS # |
60451-47-0
|
| PubChem CID |
102004666
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.644
|
| LogP |
3.16
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
86
|
| Complexity |
2390
|
| Defined Atom Stereocenter Count |
33
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)[C@@]45CC[C@@]6(C(=CC[C@H]7[C@]6(CC[C@@H]8[C@@]7(CC[C@@H]([C@@]8(C)CO)O[C@H]9[C@@H]([C@H]([C@H](CO9)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C)C)[C@@H]4CC(CC5)(C)C)C)O)O)O)O)O)O)O)O)O
|
| InChi Key |
KWXBKEINOHVSGJ-FBCAOFFQSA-N
|
| InChi Code |
InChI=1S/C59H96O27/c1-24-34(63)39(68)43(72)48(80-24)78-21-29-37(66)41(70)44(73)49(82-29)79-22-30-38(67)42(71)46(75)51(83-30)86-53(76)59-16-14-54(2,3)18-26(59)25-8-9-32-55(4)12-11-33(56(5,23-61)31(55)10-13-58(32,7)57(25,6)15-17-59)84-52-47(35(64)27(62)20-77-52)85-50-45(74)40(69)36(65)28(19-60)81-50/h8,24,26-52,60-75H,9-23H2,1-7H3/t24-,26-,27-,28+,29+,30+,31+,32+,33-,34-,35-,36+,37+,38+,39+,40-,41-,42-,43+,44+,45+,46+,47+,48+,49+,50-,51-,52-,55-,56-,57+,58+,59-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxan-2-yl] (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~80.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8082 mL | 4.0408 mL | 8.0816 mL | |
| 5 mM | 0.1616 mL | 0.8082 mL | 1.6163 mL | |
| 10 mM | 0.0808 mL | 0.4041 mL | 0.8082 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
